{"id":866751,"date":"2025-07-07T07:33:45","date_gmt":"2025-07-07T11:33:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/"},"modified":"2025-07-07T07:33:45","modified_gmt":"2025-07-07T11:33:45","slug":"organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/","title":{"rendered":"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis"},"content":{"rendered":"<p>        <!--.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Organon\u2019s VTAMA<sup>\u00ae<\/sup> (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe American Academy of Dermatology (AAD) provides a strong evidence-based recommendation for the use of VTAMA cream<b \/>in adults with moderate to severe atopic dermatitis (AD), the most common form of eczema.<\/p>\n<\/li>\n<li>\nRecommendation reflects VTAMA cream\u2019s proven efficacy, safety, and tolerability as a steroid-free, topical aryl hydrocarbon receptor agonist.<\/p>\n<\/li>\n<li>\nAD impacts 26 million people in the United States, 16.5 million of which are adults.<\/p>\n<\/li>\n<\/ul>\n<p>JERSEY CITY, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nOrganon (NYSE: OGN), a global independent healthcare company with a focus on women\u2019s health, today announced that VTAMA<sup>\u00ae<\/sup> (tapinarof) cream, 1%,<b \/>was granted a strong recommendation by the American Academy of Dermatology (AAD) in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD). The recommendation underscores VTAMA cream as an effective, steroid-free option for daily disease management, with no label warnings or precautions, no contraindications, and no restrictions on duration of use or percentage of body surface area affected. In AD, the most common adverse reactions (incidence \u22651%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.<\/p>\n<p>\n\u201cWith 6.6 million adults in the US living with moderate to severe AD, innovative treatment options that meet the highest standards for efficacy, safety, and tolerability are necessary to help provide lasting relief. We are proud of the AAD\u2019s strong evidence-based recommendation from the ADORING 1 and ADORING 2 8-week clinical trials for VTAMA cream\u2014a once daily, steroid-free topical with no label restrictions on use based on disease severity, percentage of body surface area affected, or duration of use,\u201d said Juan Camilo Arjona Ferreira, Head of Research and Development and Chief Medical Officer at Organon. \u201cThis strong recommendation, paired with the findings from our Phase 3 ADORING 3 48-week, open-label, long-term extension study which uncovered the possibility of a treatment-free interval lasting on average 80 days after treatment success, highlights how VTAMA cream has the potential to redefine the AD treatment landscape and provide lasting results.\u201d<\/p>\n<p>\nThe focused update incorporates topical and systemic therapies that have been recently approved by the US Food and Drug Administration (FDA) into the AAD\u2019s existing guidance on the management of AD in adults to ensure the dermatology community has access to the best available evidence.<\/p>\n<p>\nIn December 2024, the FDA approved VTAMA cream for the topical treatment of AD in adults and pediatric patients 2 years of age and older. VTAMA cream was also approved by the FDA on May 24, 2022, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults.<\/p>\n<p><b>INDICATIONS:<\/b> VTAMA<sup>\u00ae<\/sup> (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nthe topical treatment of plaque psoriasis in adults<\/p>\n<\/li>\n<li>\nthe topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older<\/p>\n<\/li>\n<\/ul>\n<p><b>SELECTED SAFETY INFORMATION<\/b><\/p>\n<p><b>Adverse Events:<\/b> In plaque psoriasis, the most common adverse reactions (incidence \u22651%) were: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.<\/p>\n<p><b>Adverse Events:<\/b> In atopic dermatitis, the most common adverse reactions (incidence \u22651%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.<\/p>\n<p>\nYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=www.fda.gov%2Fmedwatch&amp;index=1&amp;md5=7671dac1bcef60ebd84a69c3e2f30e14\">www.fda.gov\/medwatch<\/a> or call 1-800-FDA-1088.<\/p>\n<p><b>Before prescribing VTAMA cream, please read the <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vtama.com%2FPI%2F&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=2&amp;md5=058037639419aaf78aff5df375c09b78\"><b>Prescribing Information<\/b><\/a><b>.<\/b><\/p>\n<p>\nFor more information about VTAMA (tapinarof) cream, 1%, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvtamahcp.com%2F&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=www.vtamahcp.com&amp;index=3&amp;md5=b2841fd1f989a4f360fb6becc10ca1f8\">www.vtamahcp.com<\/a>.<\/p>\n<p><b>About Atopic Dermatitis<\/b><\/p>\n<p>\nAD, commonly referred to as eczema, is one of the most prevalent inflammatory skin diseases, affecting over 26 million people in the US alone and up to 10% of adults worldwide.<sup>1,2<\/sup> AD occurs most frequently in children, affecting up to 20% worldwide.<sup>1,2<\/sup> The disease results in itchy, red, swollen, and cracked skin, often on the folds of the arms, back of the knees, hands, face, and neck.<sup>3<\/sup> Itching is an especially bothersome symptom for those with AD, and tends to worsen at night, which can disturb sleep.<sup>1<\/sup><\/p>\n<p><b>About Organon<\/b><\/p>\n<p>\nOrganon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women\u2019s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately, or differently affect women, while expanding access to essential treatments in over 140 markets.<\/p>\n<p>\nHeadquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.organon.com%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911899344%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DtKCOYU9vOLmDCTcWEb78bIZkuNDXd%252FDCaFpmAXlvpmA%253D%26reserved%3D0&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=www.organon.com&amp;index=4&amp;md5=e349ef3ad42261e3b5124d787f78acf9\">www.organon.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Forganon%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911924697%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DXpwhK7dRFG4u0%252BtB6G3zuil0nV8BmZEg5PesVDdjQRg%253D%26reserved%3D0&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=969a6642946727c0476dca9512db2981\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.instagram.com%252Forganonllc%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911936373%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DqSg1VM84RxtKG6QfoItRTlHJRW5y41wCaOhpLSJxtPc%253D%26reserved%3D0&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=afceb186ceb6f52bc6e3419c31e62c5b\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fx.com%252FOrganonLLC%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911949591%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DeNbT%252B%252Bj03w5tIXxRnwJEaolZePGmNi70pPL3bdaBqB8%253D%26reserved%3D0&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=X&amp;index=7&amp;md5=bdd8e3879c0e997eb31cc3b8a77c540d\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.youtube.com%252Fchannel%252FUCFXZcWljXuEhDkMCmZZ4Yzw%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911965966%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DOg8MAaURoWgydvBUAsbzysy2m1CB8MPigwCnj6ExGoQ%253D%26reserved%3D0&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=0b346dde5a0273cea690e0825e1c2b96\">YouTube<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.tiktok.com%252F%2540organon_llc%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911978302%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DuJyzKNE%252BI7PIJqk1ALN3CSuX%252BnT1HlV%252Ba2Y4sdtQ22Q%253D%26reserved%3D0&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=TikTok&amp;index=9&amp;md5=2279709bb42ce42456a55b654c566dae\">TikTok<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.facebook.com%252FOrganonLLC%252F%26data%3D05%257C02%257Cjanine.colavita%2540organon.com%257Cb0e062228892414c51c208ddb7d498dc%257C484a70d1caaf4a03a4771cbe688304af%257C0%257C0%257C638868845911991988%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DL32i3wTDxRkuvRdV%252BvbEx4BxQwEzlcgX%252FMghX5QCxLs%253D%26reserved%3D0&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=Facebook&amp;index=10&amp;md5=2a9ee44274f4c2368073d1a6e7899781\">Facebook<\/a>.<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nExcept for historical information, this press release includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon\u2019s expectations about the potential impact of VTAMA as a treatment option for AD. Forward-looking statements may be identified by words such as \u201cpotential,\u201d \u201cmission,\u201d \u201cexpects,\u201d \u201cwill,\u201d or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon\u2019s filings with the SEC, including Organon\u2019s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=11&amp;md5=e2e784aa930b38e4d881ff258c398a0e\">www.sec.gov<\/a>). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n____________________<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><sup>1 Eczema stats. National Eczema Association. Accessed June 5, 2025. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F&amp;index=12&amp;md5=95e958a28d808f2c35c1c8066e805634\">https:\/\/nationaleczema.org\/research\/eczema-facts\/<\/a><\/sup><\/p>\n<p><sup>2 Global Report on Atopic Dermatitis 2022. International League of Dermatological Societies: 2022. Accessed February 25, 2025. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.eczemacouncil.org%2Fassets%2Fdocs%2Fglobal-report-on-atopic-dermatitis-2022.pdf&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.eczemacouncil.org%2Fassets%2Fdocs%2Fglobal-report-on-atopic-dermatitis-2022.pdf&amp;index=13&amp;md5=a94fab66a7bf26db01c6c87f5a291373\">https:\/\/www.eczemacouncil.org\/assets\/docs\/global-report-on-atopic-dermatitis-2022.pdf<\/a><\/sup><\/p>\n<p><sup>3 What is eczema? National Eczema Association. Accessed July 2, 2025. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnationaleczema.org%2Feczema%2F&amp;esheet=54285710&amp;newsitemid=20250707974353&amp;lan=en-US&amp;anchor=https%3A%2F%2Fnationaleczema.org%2Feczema%2F&amp;index=14&amp;md5=05fcb9977696a29e11cba47b80bcc1b5\">https:\/\/nationaleczema.org\/eczema\/<\/a><\/sup><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250707974353\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250707974353\/en\/<\/a><\/span><\/p>\n<p>\nMedia Contacts:<\/p>\n<p>\nJanine Colavita<br \/>\n<br \/>(732) 861-3806<\/p>\n<p>\nFelicia Bisaro<br \/>\n<br \/>(646) 703-1807<\/p>\n<p>\nInvestor Contact:<\/p>\n<p>\nJennifer Halchak<br \/>\n<br \/>(201) 275-2711<\/p>\n<p><b>KEYWORDS:<\/b> United States North America New Jersey<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Consumer Women Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250707974353\/en\/1899942\/3\/Organon_Logo_No_tagline.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis The American Academy of Dermatology (AAD) provides a strong evidence-based recommendation for the use of VTAMA creamin adults with moderate to severe atopic dermatitis (AD), the most common form of eczema. Recommendation reflects VTAMA cream\u2019s proven efficacy, safety, and tolerability as a steroid-free, topical aryl hydrocarbon receptor agonist. AD impacts 26 million people in the United States, 16.5 million of which are adults. JERSEY CITY, N.J.&#8211;(BUSINESS WIRE)&#8211; Organon (NYSE: OGN), a global independent healthcare company with a focus on women\u2019s health, today announced that VTAMA\u00ae (tapinarof) cream, 1%,was granted a strong recommendation by the American Academy of Dermatology (AAD) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866751","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis The American Academy of Dermatology (AAD) provides a strong evidence-based recommendation for the use of VTAMA creamin adults with moderate to severe atopic dermatitis (AD), the most common form of eczema. Recommendation reflects VTAMA cream\u2019s proven efficacy, safety, and tolerability as a steroid-free, topical aryl hydrocarbon receptor agonist. AD impacts 26 million people in the United States, 16.5 million of which are adults. JERSEY CITY, N.J.&#8211;(BUSINESS WIRE)&#8211; Organon (NYSE: OGN), a global independent healthcare company with a focus on women\u2019s health, today announced that VTAMA\u00ae (tapinarof) cream, 1%,was granted a strong recommendation by the American Academy of Dermatology (AAD) &hellip; Continue reading &quot;Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T11:33:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis\",\"datePublished\":\"2025-07-07T11:33:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/\"},\"wordCount\":1052,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/\",\"name\":\"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-07-07T11:33:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/","og_locale":"en_US","og_type":"article","og_title":"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis - Market Newsdesk","og_description":"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis The American Academy of Dermatology (AAD) provides a strong evidence-based recommendation for the use of VTAMA creamin adults with moderate to severe atopic dermatitis (AD), the most common form of eczema. Recommendation reflects VTAMA cream\u2019s proven efficacy, safety, and tolerability as a steroid-free, topical aryl hydrocarbon receptor agonist. AD impacts 26 million people in the United States, 16.5 million of which are adults. JERSEY CITY, N.J.&#8211;(BUSINESS WIRE)&#8211; Organon (NYSE: OGN), a global independent healthcare company with a focus on women\u2019s health, today announced that VTAMA\u00ae (tapinarof) cream, 1%,was granted a strong recommendation by the American Academy of Dermatology (AAD) &hellip; Continue reading \"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-07T11:33:45+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis","datePublished":"2025-07-07T11:33:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/"},"wordCount":1052,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/","name":"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-07-07T11:33:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707974353r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organons-vtama-tapinarof-cream-1-granted-strong-recommendation-in-the-american-academy-of-dermatology-updated-2025-guidelines-for-adult-atopic-dermatitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Organon\u2019s VTAMA\u00ae (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866751"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866751\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}